跳至主要内容
临床试验/CTRI/2013/03/003477
CTRI/2013/03/003477招募中4 期

An exploratory, observational study to evaluate the efficacy and safety of daptomycin in treating neutropenic patients with fever due to known or suspected gram positive infections in adult hemato-oncology patients.

ovartis Healthcare Pvt Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1.Patients of either gender, above the age of 18 years, who have received atleast 1 dose on daptomycin
  • 2.Hemato-Oncology patients with diagnosis of neutropenic fever
  • oTemperature 38.3 degrees C once OR greater than or equal to 38 degrees C twice within 12 hours
  • oAbsolute neutrophil count 500/cubic mm and greater than or equal to 1 of the following:
  • ï?§Mucositis
  • ï?§Concurrent skin or soft tissue infection
  • ï?§Indwelling catheter and/or suspected catheter infection
  • ï?§Recent quinolone prophylaxis
  • ï?§Positive blood cultures for gram-positive cocci before final identification Known Colonization with β-lactam resistant gram-positive organisms (commonly the nares or the skin)
  • ï?§Hypotension, tachycardia, narrowed pulse pressures, tachypnea, or other signs of cardiovascular compromise
  • oExpected duration of neutropenia greater than or equal to 3 days
  • 3.Have a life expectancy of greater than or equal to 2 weeks.
  • 4.Have performance status with an Eastern Cooperative Oncology Group score of less than or equal to 2.
  • 5.Creatinine clearance greater than or equal to 30 mL/min
  • 6.Negative pregnancy test [Note : Fertile patients must use effective double-method contraception]
  • 7.No psychiatric disorders that would preclude study compliance, No HIV positivity.
  • 8.No suspected meningitis or osteomyelitis.
  • 9.No documented or suspected gram-positive pneumonia
  • 10.No signs or symptoms of myopathy with creatine phosphokinase (CPK) elevation 1,000 U/L (5 times upper limit of normal [ULN]) [No CPK elevations 10 times ULN in patients with no signs or symptoms of myopathy]
  • 11.No known sensitivity to daptomycin or product excipients
  • 12.Patient is willing to participate in the study.

排除标准

  • 1.Known allergic reaction to daptomycin or product excipients
  • 2.Known to be infected with a daptomycin-resistant organism or a gram-negative organism and did not yet meet the criteria for the addition of antimicrobial therapy for the treatment of an infection caused by a gram-positive organism;
  • 3.Suspected meningitis or osteomyelitis
  • 4.Currently pregnant, were positive for serum human chorionic gonadotropin, or lactating
  • 5.Have a creatinine clearance (CLCR) level of 30 ml per min; or on hemodialysis or continuous ambulatory peritoneal dialysis;
  • 6.Psychiatric disorders with an inability to comply with study protocols;
  • 7.Documented or suspected pneumonia caused by a gram-positive organism;
  • 8.Life expectancy of 2 weeks;
  • 9.Have rhabdomyolysis or a history of rhabdomyolysis or have signs and symptoms of myopathy with an elevation of the creatine phosphokinase (CPK) level of 1,000 U per liter (approximately five times the upper limit of normal); or reported signs or symptoms of myopathy and elevations of the CPK level of 10 times the upper limit of normal
  • 10.Diabetic patient taking concurrent medication Piglitazone
  • 11.No concurrent hydroxymethyl glutaryl coenzyme A (HMG CoA) reductase inhibitors (e.g., lovastatin, simvastatin, atorvastatin)
  • 12.Hemoglobulin levels below 7gm per dl.
  • 13.Patient unable or unwilling to follow or comply with all study-related procedures
  • 14.Patient participating in another clinical study requiring follow-up examinations
  • 15.Patients, who in the opinion of the Investigator is not suitable for this study regimen

研究者

发起方
ovartis Healthcare Pvt Ltd

相似试验